{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:11:43Z","timestamp":1760145103692,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["21SGR25","GLD17\/00282"],"award-info":[{"award-number":["21SGR25","GLD17\/00282"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead Sciences Fellowship","award":["21SGR25","GLD17\/00282"],"award-info":[{"award-number":["21SGR25","GLD17\/00282"]}]},{"name":"Fundaci\u00f3n Espa\u00f1ola de Hematolog\u00eda y Hemoterapia (FEHH)-AstraZeneca","award":["21SGR25","GLD17\/00282"],"award-info":[{"award-number":["21SGR25","GLD17\/00282"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Current CLL guidelines recommend a two parallel cultures assessment using TPA and IL2+DSP30 mitogens for complex karyotype (CK) detection. Studies comparing both mitogens for CK identification in the same cohort are lacking. We analyzed the global performance, CK detection, and concordance in the complexity assessment of two cytogenetic cultures from 255 CLL patients. IL2+DSP30 identified more altered karyotypes than TPA (50 vs. 39%, p = 0.031). Moreover, in 71% of those abnormal by both, IL2+DSP30 identified more abnormalities and\/or abnormal metaphases. CK detection was similar for TPA and IL2+DSP30 (10% vs. 11%). However, 11\/33 CKs (33%) were discordant, mainly due to the detection of a normal karyotype or no metaphases in the other culture. Patients requiring treatment within 12 months after sampling (active CLL) displayed significantly more CKs than those showing a stable disease (55% vs. 12%, p &lt; 0.001). Disease status did not impact cultures\u2019 concordance (\u03ba index: 0.735 and 0.754 for stable and active). Although CK was associated with shorter time to first treatment (TTFT) using both methods, IL2+DSP30 displayed better accuracy than TPA for predicting TTFT (C-index: 0.605 vs. 0.580, respectively). In summary, the analysis of two parallel cultures is the best option to detect CKs in CLL. Nonetheless, IL2+DSP30 could be prioritized above TPA to optimize cytogenetic assessment in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers16122258","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T07:33:20Z","timestamp":1718696000000},"page":"2258","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complex Karyotype Detection in Chronic Lymphocytic Leukemia: A Comparison of Parallel Cytogenetic Cultures Using TPA and IL2+DSP30 from a Single Center"],"prefix":"10.3390","volume":"16","author":[{"given":"Joanna","family":"Kamaso","sequence":"first","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-4978","authenticated-orcid":false,"given":"Anna","family":"Puiggros","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Salido","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Melero","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez-Rivera","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gimeno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Applied Clinical Research in Hematological Malignances Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitari Sant Joan de Reus, 43204 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-7179","authenticated-orcid":false,"given":"Leonor","family":"Arenillas","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-9130","authenticated-orcid":false,"given":"Xavier","family":"Calvo","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eug\u00e8nia","family":"Abella","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ramos-Campoy","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-6192","authenticated-orcid":false,"given":"Rosa","family":"Collado","sequence":"additional","affiliation":[{"name":"Department of Hematology, Consorcio Hospital General Universitario Valencia, 46014 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9601-5757","authenticated-orcid":false,"given":"Marco Antonio","family":"Moro-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Laboratory Medicine Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-8145","authenticated-orcid":false,"given":"Blanca","family":"Espinet","sequence":"additional","affiliation":[{"name":"Molecular Cytogenetics and Hematological Cytology Laboratories, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain"},{"name":"Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_4","unstructured":"(2024, April 29). Chronische Lymphatische Leuk\u00e4mie (CLL) Onkopedia. Available online: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/chronische-lymphatische-leukaemie-cll\/@@guideline\/html\/index.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"54297","DOI":"10.18632\/oncotarget.17350","article-title":"Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53\/ATM FISH deletions","volume":"8","author":"Puiggros","year":"2017","journal-title":"Oncotarget"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gasc\u00f3n-Y-Mar\u00edn, I., Mu\u00f1oz-Novas, C., Rodr\u00edguez-Vicente, A.E., Quijada-\u00c1lamo, M., Hern\u00e1ndez-S\u00e1nchez, M., P\u00e9rez-Carretero, C., Ramos-Ascanio, V., and Hern\u00e1ndez-Rivas, J.\u00c1. (2021). From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. Cancers, 13.","DOI":"10.3390\/cancers13081782"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000533704","article-title":"Prognostic Markers in the Era of Targeted Therapies","volume":"147","author":"Kang","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1097\/HS9.0000000000000707","article-title":"Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations","volume":"6","author":"Baliakas","year":"2022","journal-title":"Hemasphere"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/gcc.20691","article-title":"Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study","volume":"48","author":"Put","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/sj.leu.2404935","article-title":"Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping","volume":"21","author":"Haferlach","year":"2007","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","article-title":"Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells","volume":"95","author":"Decker","year":"2000","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2006-02-005322","article-title":"Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression","volume":"108","author":"Dicker","year":"2006","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/leu.2008.252","article-title":"Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities","volume":"23","author":"Struski","year":"2009","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-014-1681-0","article-title":"CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Liaw","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan, J., Hastings, R.J., and Moore, S. (2020). ISCN 2020: An International System for Human Cytogenomic Nomenclature, Karger.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41416-019-0502-x","article-title":"The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia","volume":"121","author":"Visentin","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ajh.25956","article-title":"The complex karyotype and chronic lymphocytic leukemia: Prognostic value and diagnostic recommendations","volume":"95","author":"Jondreville","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood.2020010536","article-title":"The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib","volume":"138","author":"Kittai","year":"2021","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood.2021011883","article-title":"Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: The GIMEMA LLC1114 phase 2 study","volume":"138","author":"Rigolin","year":"2021","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.2023019634","article-title":"High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations","volume":"142","author":"Thus","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Puiggros, A., Ramos-Campoy, S., Kamaso, J., de la Rosa, M., Salido, M., Melero, C., Rodr\u00edguez-Rivera, M., Bougeon, S., Collado, R., and Gimeno, E. (2022). Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). Cancers, 14.","DOI":"10.3390\/cancers14143376"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Valkama, A., Vorimo, S., Kumpula, T.A., R\u00e4s\u00e4nen, H., Savolainen, E.R., Pylk\u00e4s, K., and Mantere, T. (2023). Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15041294"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2258\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:00:33Z","timestamp":1760108433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/12\/2258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["cancers16122258"],"URL":"https:\/\/doi.org\/10.3390\/cancers16122258","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}